Hemangioma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
A paradigm shift has occurred regarding the treatment of hemangiomas over the past few years. In 2008, propranolol, a nonselective β-adrenergic antagonist, was serendipitously discovered to cause regression of proliferating hemangiomas in newborns receiving treatment for cardiovascular disease | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 18:50, 13 November 2015
|
Hemangioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemangioma medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemangioma medical therapy |
|
Risk calculators and risk factors for Hemangioma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Medical Therapy
A paradigm shift has occurred regarding the treatment of hemangiomas over the past few years. In 2008, propranolol, a nonselective β-adrenergic antagonist, was serendipitously discovered to cause regression of proliferating hemangiomas in newborns receiving treatment for cardiovascular disease